Meeting
2015 ASCO Annual Meeting
Predictive testing for selection of patients for extended endocrine therapy: Clinical utilization of Breast Cancer Index (BCI) in early-stage, ER+, LN- breast cancer.
Authors
Stephen C. Malamud
Beth Israel Medcl Ctr, New York, NY
Stephen C. Malamud , Brock Schroeder , Theresa N. Operana , Catherine A. Schnabel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 545)
DOI
10.1200/jco.2015.33.15_suppl.545
Abstract #
545
Poster Bd #
33
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Clinical utilization of Breast Cancer Index (BCI) for late recurrence risk assessment and prediction of extended endocrine therapy (EET) benefit in early stage HR+ breast cancer.
First Author: Reshma L. Mahtani
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden
Poster
2015 ASCO Annual Meeting
Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy.
First Author: Tara Beth Sanft
Poster
2023 ASCO Annual Meeting
An analysis of breast cancer index scores predicting benefit of extended endocrine therapy by race.
First Author: Nicholas Siu-Li